Tarsons Products Limited · NSE:TARSONS
Tarsons Products — Q4 FY2024 Earnings Presentation
34 slides from Tarsons Products's earnings presentation, May 30, 2024
Slide 1: Exchange filing cover letter for investor presentation
An ISO 9001 & ISO 13485 Certified Company Date: 30th May, 2024 To, To, BSE Limited (“BSE”), National Stock Exchange of India Limited (“NSE”) Corporate Relationship Department, “Exchange Plaza”, 5th Floor, 2nd Floor, New Trading Ring, Plot No. C/1, G Block, P.J. Towers, Dalal Street, Bandra-Kurla Com
Slide 2: Tarsons Products Limited Investor Presentation May 2024
TARSONS PRODUCTS LIMITED Investor Presentation May 2024 TRUST DELIVERED
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q4 & FY24 Financial Highlights
Q4 & FY24 Financial Highlights
Slide 5: Key Highlights
Key Highlights ➢ Achieved Highest ever Quarterly Standalone revenue of Rs. 87 crores in Q4FY24 ➢ Acquisition of Nerbe has been successfully completed, alongside we are working on synergies to increase operational efficiencies and cross selling of products to increase our penetration in the exports m
Slide 6: Q4 & FY24 Key Standalone Operational Highlights
Q4 & FY24 Key Standalone Operational Highlights (in Rs. Crs) 283 277 Revenue Spilt – Domestic : 191 33% 30% 194 Export FY23 FY24 82 87 62 67% 70% 58 59 46 92 83 25 15 28 Q4FY23 Q3FY24 Q4FY24* FY23 FY24 Domestic Exports ➢ Revenues from exports in Q4FY24 stood at Rs. 28 crs as compared to Rs. 25 crs i
Slide 7: Q4 & FY24 Key Standalone Financial Highlights
Q4 & FY24 Key Standalone Financial Highlights Revenue (in Rs. Crs) EBIDTA (in Rs. Crs) Profit After Tax (in Rs. Crs) ➢ Highest Ever quarterly Revenue of Rs. 87 crores in 283.3 129.8 80.7 277.3 Q4FY24, growth of 6% Y-o-Y & 51.2 82.1 86.6 106.2 40% Q-o-Q 61.8 39.3 33.9 ➢ Gross Profit & EBITDA Margin 2
Slide 8: Q4 & FY24 Key Consolidated Financial Highlights
Q4 & FY24 Key Consolidated Financial Highlights Revenue (in Rs. Crs) EBIDTA (in Rs. Crs) Profit After Tax (in Rs. Crs) 296.4 129.8 80.7 ➢ Consolidated revenues for 283.3 42.6 Q4FY24 stood at Rs. 106 crs 105.7 102.6 82.1 39.3 ➢ Consolidated revenues include 61.8 22.8 30.2 revenue from Nerbe of Rs. 19
Slide 9: Bridge between Standalone & Consolidated PBT
Bridge between Standalone & Consolidated PBT 69.4 5.6 Interest income and Guarantee Commission booked in Tarsons on Loan given to Singapore Subsidiary, which got knocked off on Consolidation One-off expenses booked in Singapore subsidiary on account of Acquisition 3.1 Profit earned by Nerbe before t
Slide 10: Management Commentary
Management Commentary Commenting on the performance of the company Mr. Rohan Sehgal, Executive Director of Tarsons, said: “In the recent past, the life science industry has experienced turmoil amidst slowdowns, global recessionary trends, inventory unwinding, and geopolitical tensions. Despite these
Slide 11: Q4 & FY24 Standalone Profit & Loss Statement
Q4 & FY24 Standalone Profit & Loss Statement Profit and Loss (in Rs. Crs) Q4FY24 Q4FY23 YoY Q3FY24 QoQ FY24 FY23 YoY Revenue from Operations 86.6 82.1 5.6% 61.8 40.2% 277.3 283.2 -2.1% Cost of Goods Sold 23.8 20.3 16.7 72.8 65.1 Gross Profit 62.8 61.7 1.8% 45.1 39.2% 204.5 218.2 -6.3% Gross Profit M
Slide 12: Q4 & FY24 Consolidated Profit & Loss Statement
Q4 & FY24 Consolidated Profit & Loss Statement Profit and Loss (in Rs. Crs) Q4FY24 FY24 Revenue from Operations 105.7 296.4 Cost of Goods Sold 33.2 82.2 Gross Profit 72.5 214.2 Gross Profit Margin 68.6% 72.3% Employee Cost 15.6 44.3 Other Expenses 26.7 63.6 Adj. EBITDA 33.9 106.3 Adj. EBITDA Margin
Slide 13: Balance Sheet
Balance Sheet Consolidated Standalone Consolidated Standalone Assets (in Rs. Crs) Equity & Liabilities (in Rs. Crs) Mar-24 Mar-24 Mar-23 Mar-24 Mar-24 Mar-23 Non - Current Assets 736.9 761.1 473.7 Total Equity 612.9 620.4 569.3 Property Plant & Equipment's 247.8 244.9 217.7 Share Capital 10.6 10.6 1
Slide 14: Cash Flow Statement
Cash Flow Statement Consolidated Standalone Particulars (Rs. Crs) FY24 FY24 FY23 Net Profit Before Tax 60.8 69.4 108.7 Adjustments for: Non -Cash Items / Other Investment or Financial Items 51.8 47.0 27.5 Operating profit before working capital changes 112.5 116.4 136.2 Changes in working capital 8.
Slide 15: About Tarsons
TRUST DELIVERED
Slide 16: Tarsons – at a Glance
Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm
Slide 17: Our Journey
Our Journey Established Product portfolio Commenced Pioneered the first fully manufacturing facility expansion & adding Established line for PCR production of Pipette robotic clean room expanding into depth in existing products in Jalan Tips, thereby creating a plant for manufacturing production of
Slide 18: Leading Indian Labware Supplier
Leading Indian Labware Supplier Trusted Brand for high quality Expertise in production of a wide range Ability to offer differentiated, user products in the plastic labware of labware products & amongst the friendly, reliable quality & cost-effective market with 40+ years vintage in the top 3 player
Slide 19: Our Competitive Edge
Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution sector with strong brand recognition and network high-quality diversified products across varied customer segments. 03 04 State of Art F
Slide 20: Catering to diversified End User Industry
Catering to diversified End User Industry… Measures to strengthen customer relations Academic Institutes National Centre Indian Institute of Rain Forest KIIT Regular Feedback from Customers on quality, & Research for Biological Chemical Research Institute University 1 delivery & cost Sciences Techno
Slide 21: Our State-of-the-art Manufacturing Facilities
Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in-house ✓ Automated manufacturing with use of robotics & other technologies developed in collabora
Slide 22: Widespread Domestic Sales & Distribution network
…with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 15% of FY24 Domestic Sales East: 16% of FY24 Domestic Sales 43 Distributors 41 Distributors West: 24% of FY24 Domestic Sales 22 Distributors South
Slide 23: Huge underlying Export Market Potential
…with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2024, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at 10% CAGR for developing ✓ Export op
Slide 24: Offering Wide Range of High-Quality Products
…offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachables Consumables Reusables Others 55% of FY24 40% of FY24 5% of FY24 Revenues Revenues Revenues • Portfolio of
Slide 25: Diversified product portfolio of Plastic Labware
…diversified product portfolio of Plastic Labware Centrifuge Sterile Media Pipette Tips Petri Dishes Cryo Vials Storage Vials Serological Pipette Tubes Bottles Consumables (55% of FY24 Sales) • Mostly used in culture Designed for use Disposable pipettes Suited to preparation Used for storage of Perf
Slide 26: Glimpse of our product portfolio & processes
Glimpse of our product portfolio & processes Video link – Click here Video link – Click here Video link – Click here Video link – Click here Video link – Click here For more information & videos please visit www.tarsons.com/video-new 25
Slide 27: Key Business Strategies
Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro
Slide 28: Experienced Board of Director & Managerial Team
Experienced Board of Director & Managerial Team Gaurav Podar Sanjive Sehgal Non-Executive Nominee Director Chairman & Managing Director • Currently, Director with ADV Partners • Chairman & Managing Director of Tarsons • Investment professional with 11+ years of experience Product Limited • Has over
Slide 29: Contribution towards Environmental, Social & Governance
Contribution towards Environmental, Social & Governance Clean room conditions eliminates all chances of Use of Medical Grade NO litigations faced for pollution or contamination Plastics. Products are designed to degradation of environment over the withstand critical use past five years Productivity
Slide 30: Industry Update
DELIVERING TRUST
Slide 31: Plastic Labware Market
Plastic Labware Market Indian plastic labware market is expected to grow at 16% CAGR from 2020- Split of Global Market Size of Plastic Labware (2020) 2025 Certrifuge ▪ Centrifuge & Liquid Handling Global Laboratory Equipment Indian Laboratory Equipment ware market dominate the Laboratory Market Size
Slide 32: Rapid Shift from Glassware to Plasticware in India
Rapid Shift from Glassware to Plasticware in India Indian Laboratory Equipment Market (Breakup of Glassware and Plasticware segments) INR 10.8 bn INR 11.3 bn INR 8.4 bn Key reasons for the shift: Market Size INR 7.5 bn INR 12.2 bn INR 25.8 bn ▪ Increased Applicability: Superior ability to handle rad
Slide 33: Key Takeaways
Key Takeaways Leading Indian manufacturer of Financial profile with Historical labware with an established brand strong EBITDA margins & high & focus on high-quality products ROCE Presence in an industry with Highly automated state-of-the-art double-digit growth potential and manufacturing facilitie
Slide 34: Thank You
Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff/ Mr. Pratik Shah santosh@tarsons.in sagar.shroff@sgapl.net / p.s.shah@sgapl.net +91 98205 19303 / +91 9870